News | News By Subject | News by Disease News By Date | Search News

Multiple sclerosis (MS) News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
3 Reasons That Make Biogen (BIIB) the King of a Crumbling Empire     11/14/2016
Opexa Therapeutics (OPXA) Stock Tanks After Failed MS Trial, Cuts 40% Staff     11/2/2016
Teva (TEVA) Stock Plummets After Two Patents are Invalidated by Mylan (MYL)     8/25/2016
Novartis AG (NVS) Touts Phase III Data for MS Drug Siponimod     8/25/2016
Speedy Review for Genentech (RHHBY)’s OCREVUS, Action Date December 28     6/29/2016
Biogen (BIIB) Loses $8 Billion in Market Value in One Day After Failed Trial     6/8/2016
Biogen (BIIB)'s Stock Falls as MS Drug Fails to Meet Endpoints in Mid-Stage Study     6/7/2016
Why Biogen (BIIB) Needs Yet Another Multiple Sclerosis Drug     6/3/2016
FDA Approves Biogen (BIIB) and AbbVie (ABBV)'s Once-Monthly MS Drug Zinbryta     6/2/2016
MedDay Secures $38.5 Million to Push MS Drug into Phase III Trials     4/8/2016
Bay Area's XenoPort (XNPT) Snags Psoriasis and MS Deal Worth $490 Million+ from Dr. Reddy's Laboratories Ltd. (RDY)     3/28/2016
Roche (RHHBY)'s Multiple Sclerosis Drug Gets Breakthrough Status, Likely to Haunt Biogen (BIIB)     2/18/2016
Teva (TEVA), Active Biotech (BTPC) Stop Higher Doses of Laquinimod in Two Multiple Sclerosis Trials     1/4/2016
Sanofi (SNY) Walks Away from a $613 Million Multiple Sclerosis Pact with Glenmark Pharma     10/30/2015
Positive Late-Stage Data Leads Alkermes (ALKS) to Believe it Can File an NDA for ALKS 8700 in 2018     10/29/2015

News from Around the Web
Celgene (CELG) Could Dethrone Biogen (BIIB) in Multiple Sclerosis     9/29/2016
Brain Inflammation Linked To Depression In MS Patients, King's College London Study     7/8/2016
Poor Sleep And Thinking Problems In MS Patients, University of Michigan Study     6/21/2016
Allergy Med Might Also Fight MS-Linked Eye Damage, UCSF Study     4/14/2016
Binging On Coffee May Cut Your MS Risk, Study Published In BMJ     3/7/2016
Why It Feels So Good To Scratch An Itch, Published In Proceedings Of The Entomological Society Of Washington     2/29/2016
Sun Exposure During Teen Years May Delay Onset Of MS, Copenhagen University Hospital Study     10/8/2015
Genentech (RHHBY) May Have a $5 Billion MS Blockbuster on Its Hands     9/29/2015
Low Vitamin D Linked To MS, McGill University Study     8/27/2015
Drugs Help MS Patients Create New Stem Cells To Replace Lost Brain Cells, Case Western Reserve University Study     4/22/2015
Biogen Idec (BIIB) Tests Use of Wearables to Track MS Patient Activity     3/11/2015
Can Coffee Cut Your MS Risk? Johns Hopkins University Study     3/2/2015
Diet Affects Brain Iron Levels Differently In Men And Women, University at Buffalo Study Shows     1/27/2015
The Smart Mouse With The Half-Human Brain, University of Rochester Medical Center Study     12/3/2014
Cells From Placentas Safe For Patients With Multiple Sclerosis, Mount Sinai School of Medicine Study     9/30/2014

Press Releases
Biogen (BIIB) And AbbVie (ABBV) Receive Health Canada Approval Of Once-Monthly ZINBRYTA (Daclizumab Beta) For Multiple Sclerosis     12/9/2016
Perrigo (PRGO) Reviewing Strategic Alternatives for MS Drug Tysabri     11/10/2016
Opexa Therapeutics (OPXA)' Stock Slammed After MS Candidate Flunks Phase II Test     10/28/2016
RedHill Biopharma (RDHL) Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis     10/18/2016
Merck KGaA (MKGAF.PK) Hands Back Novel Multiple Sclerosis Drug to Apitope     10/17/2016
Roche (RHHBY) Says New MS Drug Works Better Than Merck & Co. (MRK)'s Rebif     9/19/2016
Novartis AG (NVS) Drug For Multiple Sclerosis Shows Reduction In Risks     9/19/2016
FDA Takes Back Special Protocol Assessment for Active Biotech (BTPC)'s Laquinimod     9/19/2016
Merck & Co. (MRK) Presents New Data Examining Durable Efficacy With Investigational Cladribine Tablets In Multiple Sclerosis     9/16/2016
Treatment Effects Maintained Over Six Years In Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme (SNY)’s Lemtrada (Alemtuzumab) In Clinical Trials     9/16/2016
Celgene International Sárl (CELG) Release: Oral Ozanimod Efficacy And Safety Results At 2 Years From Phase II RADIANCE Trial Of Patients With Relapsing Multiple Sclerosis Presented At 32nd ECTRIMS     9/16/2016
Results From 1,000-Patient, Global Real-World Patient-Reported Outcomes Study Of Sanofi Genzyme (SNY)’s Aubagio (Teriflunomide) In Patients With Relapsing Multiple Sclerosis Demonstrate High Levels Of Treatment Satisfaction     9/15/2016
AbbVie (ABBV) And Biogen (BIIB) Release: New Data Presented At ECTRIMS Reinforce Efficacy Of ZINBRYTA (Daclizumab) And Support Long-Term Safety Profile     9/15/2016
Biogen (BIIB) Shows Off New Tecfidera Data in MS Trials     9/14/2016
Genentech (RHHBY) Release: Phase III Efficacy Results Of Investigational Medicine OCREVUS (Ocrelizumab) Reinforced By Exploratory Analyses In Two Forms Of Multiple Sclerosis     9/14/2016

//-->